NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the Quarter ended 30th June 202310-08-2023
10-08-2023
Natco Pharma Results Earnings Call for Q1FY24
Conference Call with Natco Pharma Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.10-08-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Extracts of the Newspaper Publication of Unaudited Financial Results for the Quarter ended 30th June, 2023 and notice of Interim Dividend and Record date10-08-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Audio recording of Concall Q1FY202410-08-2023
Natco Phama Q1 net profit up 31 pc at 420 cr
Total revenue increased 26.3 per centto 1,160 crore09-08-2023
Q1FY24 Quarterly Result Announced for Natco Pharma Ltd.
Pharmaceuticals company Natco Pharma announced Q1FY24 results: Consolidated total revenue of Rs 1,160.2 crore for Q1FY24, as against Rs 918.9 crore for Q1FY23, a growth of 26.3%. The net profit for Q1FY24, on a consolidated basis, was Rs 420.3 crore as against Rs 320.4 crore in Q1FY23, showing 31.2% growth. The company had made a provision of Rs 51.0 crore towards pending patent infringement litigation cases for its products in India (without admission of either liability for infringement or validity of such patents) and also incurred about Rs 17.0 crore towards special incentives to employees. The Board of Directors has declared an interim dividend of Rs 7/- (350%) per equity share of Rs 2/- each, for the FY24. Result PDF09-08-2023
NATCO PHARMA LTD. - 524816 - Record Date For Payment Of Interim Dividend
22nd August, 2023 is the Record date for the Interim Dividend for FY2023-2409-08-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Natco Records Rs.1160.2 Crores, consolidated revenue and Rs.420.3 crores of Profit, after Tax, for the 1st quarter, FY2023-2409-08-2023
NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting09-08-2023
NATCO PHARMA LTD. - 524816 - Unaudited Financial Results For The Quarter Ended 30Th June, 2023
Unaudited Financial Results for the quarter ended 30th June, 202309-08-2023